Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

641 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency.
Stecklein SR, Barlow W, Pusztai L, Timms K, Kennedy R, Logan GE, Seitz R, Badve S, Gökmen-Polar Y, Porter P, Linden H, Tripathy D, Hortobagyi GN, Godwin AK, Thompson A, Hayes DF, Sharma P. Stecklein SR, et al. Among authors: seitz r. JCO Precis Oncol. 2023 Sep;7:e2300197. doi: 10.1200/PO.23.00197. JCO Precis Oncol. 2023. PMID: 37972336 Free PMC article.
Clinical Activity of Pembrolizumab in a Patient With Metastatic Triple-Negative Breast Cancer Without Tumor Programmed Death-Ligand 1 Expression: A Case Report and Correlative Biomarker Analysis.
Bhatti S, Heldstab J, Lehn C, Tawfik O, Ash RM, Hout DR, Seitz RS, Bailey DB, O'Dea AP, Jensen RA, Fan F, Khan QJ, Godwin AK, Sharma P. Bhatti S, et al. Among authors: seitz rs. JCO Precis Oncol. 2017 Nov;1:1-6. doi: 10.1200/PO.17.00032. JCO Precis Oncol. 2017. PMID: 35172501 No abstract available.
Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy.
Masuda H, Harano K, Miura S, Wang Y, Hirota Y, Harada O, Jolly MK, Matsunaga Y, Lim B, Wood AL, Parinyanitikul N, Jin Lee H, Gong G, George JT, Levine H, Lee J, Wang X, Lucci A, Rao A, Schweitzer BL, Lawrence OR, Seitz RS, Morris SW, Hout DR, Nakamura S, Krishnamurthy S, Ueno NT. Masuda H, et al. Among authors: seitz rs. JCO Precis Oncol. 2022 Mar;6:e2000368. doi: 10.1200/PO.20.00368. JCO Precis Oncol. 2022. PMID: 35294223 Free PMC article.
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.
Dugo M, Huang CS, Egle D, Bermejo B, Zamagni C, Seitz RS, Nielsen TJ, Thill M, Antón-Torres A, Russo S, Ciruelos EM, Schweitzer BL, Ross DT, Galbardi B, Greil R, Semiglazov V, Gyorffy B, Colleoni M, Kelly CM, Mariani G, Del Mastro L, Blasi O, Callari M, Pusztai L, Valagussa P, Viale G, Gianni L, Bianchini G. Dugo M, et al. Among authors: seitz rs. Clin Cancer Res. 2024 Nov 1;30(21):4900-4909. doi: 10.1158/1078-0432.CCR-24-0149. Clin Cancer Res. 2024. PMID: 39308141 Free PMC article. Clinical Trial.
Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research.
Espinosa Fernandez JR, Eckhardt BL, Lee J, Lim B, Pearson T, Seitz RS, Hout DR, Schweitzer BL, Nielsen TJ, Lawrence OR, Wang Y, Rao A, Ueno NT. Espinosa Fernandez JR, et al. Among authors: seitz rs. PLoS One. 2020 Apr 30;15(4):e0231953. doi: 10.1371/journal.pone.0231953. eCollection 2020. PLoS One. 2020. PMID: 32353087 Free PMC article.
Spatial predictors of immunotherapy response in triple-negative breast cancer.
Wang XQ, Danenberg E, Huang CS, Egle D, Callari M, Bermejo B, Dugo M, Zamagni C, Thill M, Anton A, Zambelli S, Russo S, Ciruelos EM, Greil R, Győrffy B, Semiglazov V, Colleoni M, Kelly CM, Mariani G, Del Mastro L, Biasi O, Seitz RS, Valagussa P, Viale G, Gianni L, Bianchini G, Ali HR. Wang XQ, et al. Among authors: seitz rs. Nature. 2023 Sep;621(7980):868-876. doi: 10.1038/s41586-023-06498-3. Epub 2023 Sep 6. Nature. 2023. PMID: 37674077 Free PMC article.
Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype.
Harano K, Wang Y, Lim B, Seitz RS, Morris SW, Bailey DB, Hout DR, Skelton RL, Ring BZ, Masuda H, Rao AUK, Laere SV, Bertucci F, Woodward WA, Reuben JM, Krishnamurthy S, Ueno NT. Harano K, et al. Among authors: seitz rs. PLoS One. 2018 Oct 12;13(10):e0204513. doi: 10.1371/journal.pone.0204513. eCollection 2018. PLoS One. 2018. PMID: 30312311 Free PMC article.
641 results